HMGCR
Basic information
Region (hg38): 5:75336329-75364001
Links
Phenotypes
GenCC
Source:
- muscular dystrophy, limb-girdle, autosomal recessive 28 (Strong), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Statins, efficacy of; Myopathy, limb-girdle, autosomal recessive 28 | AD/AR | Musculoskeletal; Pharmacogenomic | Related to Statins, efficacy of, selection and dosage of cholesterol-lowering medications may be impacted by genotyping results; Individuals with Myopathy, limb-girdle, adult-onset have been described as responsive to medical management (with mevalonolactone) | Musculoskeletal | 15199031; 15367547; 24001602; 36745799 |
ClinVar
This is a list of variants' phenotypes submitted to
- Limb-girdle muscular dystrophy (1 variants)
- Muscular dystrophy, limb-girdle, autosomal recessive 28 (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the HMGCR gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 3 | |||||
missense | 16 | 18 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 1 | 1 | ||||
non coding | 3 | |||||
Total | 1 | 0 | 16 | 5 | 2 |
Variants in HMGCR
This is a list of pathogenic ClinVar variants found in the HMGCR region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
5-75342737-T-C | HMGCR-related disorder | Likely benign (Mar 01, 2019) | ||
5-75344257-T-A | Inborn genetic diseases | Uncertain significance (May 05, 2023) | ||
5-75344336-A-G | Muscular dystrophy, limb-girdle, autosomal recessive 28 | Pathogenic (Jun 21, 2023) | ||
5-75345615-G-A | Inborn genetic diseases | Uncertain significance (Mar 01, 2023) | ||
5-75347030-A-T | - | no classification for the single variant (-) | ||
5-75347264-G-A | Inborn genetic diseases | Uncertain significance (Jan 11, 2023) | ||
5-75350103-C-T | HMGCR-related disorder | Likely benign (Apr 18, 2019) | ||
5-75350791-T-A | HMGCR-related disorder | Likely benign (Aug 09, 2019) | ||
5-75350838-C-T | Inborn genetic diseases | Uncertain significance (Aug 17, 2021) | ||
5-75350870-A-G | Inborn genetic diseases | Uncertain significance (Jun 14, 2023) | ||
5-75350940-A-C | HMGCR-related disorder | Benign (Aug 29, 2019) | ||
5-75351073-T-A | Inborn genetic diseases | Uncertain significance (Nov 08, 2022) | ||
5-75351155-G-C | Inborn genetic diseases | Uncertain significance (Jan 20, 2023) | ||
5-75351228-T-C | Inborn genetic diseases | Uncertain significance (May 11, 2022) | ||
5-75351540-A-G | Inborn genetic diseases | Uncertain significance (Jan 25, 2024) | ||
5-75351561-C-T | Muscular dystrophy, limb-girdle, autosomal recessive 28 | Pathogenic (Jun 21, 2023) | ||
5-75351562-G-A | Muscular dystrophy, limb-girdle, autosomal recessive 28 | Pathogenic (Jun 21, 2023) | ||
5-75352778-A-T | Low density lipoprotein cholesterol level quantitative trait locus 3 | association (Mar 20, 2008) | ||
5-75354650-CCTT-C | Muscular dystrophy, limb-girdle, autosomal recessive 28 | Pathogenic (Jun 21, 2023) | ||
5-75354693-C-T | Inborn genetic diseases | Uncertain significance (Feb 11, 2022) | ||
5-75355083-A-G | Inborn genetic diseases | Uncertain significance (Jun 28, 2022) | ||
5-75355133-T-A | Inborn genetic diseases | Uncertain significance (Dec 21, 2023) | ||
5-75355435-G-A | Inborn genetic diseases | Uncertain significance (Jun 12, 2023) | ||
5-75355441-G-A | Inborn genetic diseases | Uncertain significance (Sep 08, 2023) | ||
5-75355509-G-A | Muscular dystrophy, limb-girdle, autosomal recessive 28 | Pathogenic (Jun 21, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
HMGCR | protein_coding | protein_coding | ENST00000287936 | 19 | 25776 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.999 | 0.00139 | 125733 | 0 | 14 | 125747 | 0.0000557 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 3.76 | 262 | 498 | 0.526 | 0.0000262 | 5816 |
Missense in Polyphen | 63 | 184.75 | 0.34099 | 2115 | ||
Synonymous | 1.01 | 147 | 163 | 0.900 | 0.00000817 | 1746 |
Loss of Function | 5.43 | 6 | 45.6 | 0.132 | 0.00000252 | 545 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.0000289 | 0.0000289 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000163 | 0.000163 |
Finnish | 0.0000463 | 0.0000462 |
European (Non-Finnish) | 0.0000617 | 0.0000615 |
Middle Eastern | 0.000163 | 0.000163 |
South Asian | 0.0000808 | 0.0000653 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Transmembrane glycoprotein that is the rate-limiting enzyme in cholesterol biosynthesis as well as in the biosynthesis of nonsterol isoprenoids that are essential for normal cell function including ubiquinone and geranylgeranyl proteins.;
- Pathway
- Mevalonate pathway;Bile secretion - Homo sapiens (human);AMPK signaling pathway - Homo sapiens (human);Terpenoid backbone biosynthesis - Homo sapiens (human);Bisphosphonate Pathway, Pharmacodynamics;Metformin Pathway, Pharmacodynamic;Statin Pathway, Pharmacodynamics;Simvastatin Action Pathway;Pravastatin Action Pathway;Atorvastatin Action Pathway;Hyper-IgD syndrome;Cholesteryl ester storage disease;Lysosomal Acid Lipase Deficiency (Wolman Disease);Alendronate Action Pathway;Rosuvastatin Action Pathway;Lovastatin Action Pathway;Mevalonic aciduria;Wolman disease;Risedronate Action Pathway;Cerivastatin Action Pathway;Pamidronate Action Pathway;Fluvastatin Action Pathway;Smith-Lemli-Opitz Syndrome (SLOS);Chondrodysplasia Punctata II, X Linked Dominant (CDPX2);CHILD Syndrome;Desmosterolosis;Hypercholesterolemia;Steroid Biosynthesis;Zoledronate Action Pathway;Ibandronate Action Pathway;AMP-activated Protein Kinase (AMPK) Signaling;Target Of Rapamycin (TOR) Signaling;Cholesterol Biosynthesis;Sterol Regulatory Element-Binding Proteins (SREBP) signalling;Integrated Breast Cancer Pathway;SREBF and miR33 in cholesterol and lipid homeostasis;Activation of gene expression by SREBF (SREBP);Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha);Demo complete;Demo;Statin Pathway;Metabolism of lipids;Regulation of cholesterol biosynthesis by SREBP (SREBF);Squalene and cholesterol biosynthesis;Metabolism;superpathway of cholesterol biosynthesis;Metabolism of steroids;Steroids metabolism;Cholesterol biosynthesis;Activation of gene expression by SREBF (SREBP);mevalonate pathway;superpathway of geranylgeranyldiphosphate biosynthesis I (via mevalonate)
(Consensus)
Recessive Scores
- pRec
- 0.617
Intolerance Scores
- loftool
- 0.203
- rvis_EVS
- -0.49
- rvis_percentile_EVS
- 22.36
Haploinsufficiency Scores
- pHI
- 0.894
- hipred
- Y
- hipred_score
- 0.783
- ghis
- 0.637
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- E
- essential_gene_gene_trap
- E
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.998
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Hmgcr
- Phenotype
- liver/biliary system phenotype; growth/size/body region phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; homeostasis/metabolism phenotype;
Zebrafish Information Network
- Gene name
- hmgcrb
- Affected structure
- ethmoid cartilage
- Phenotype tag
- abnormal
- Phenotype quality
- shortened
Gene ontology
- Biological process
- cholesterol biosynthetic process;ubiquinone metabolic process;aging;response to nutrient;isoprenoid biosynthetic process;visual learning;negative regulation of striated muscle cell apoptotic process;positive regulation of cardiac muscle cell apoptotic process;coenzyme A metabolic process;sterol biosynthetic process;regulation of lipid metabolic process;positive regulation of stress-activated MAPK cascade;negative regulation of MAP kinase activity;myoblast differentiation;response to ethanol;regulation of cholesterol biosynthetic process;positive regulation of skeletal muscle tissue development;positive regulation of smooth muscle cell proliferation;protein tetramerization;oxidation-reduction process;negative regulation of wound healing;negative regulation of insulin secretion involved in cellular response to glucose stimulus;positive regulation of ERK1 and ERK2 cascade;negative regulation of blood vessel diameter
- Cellular component
- peroxisomal membrane;endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane
- Molecular function
- hydroxymethylglutaryl-CoA reductase (NADPH) activity;protein binding;hydroxymethylglutaryl-CoA reductase activity;protein homodimerization activity;coenzyme binding;protein phosphatase 2A binding;NADPH binding